ScionxBio has entered into a worldwide strategic collaboration and licensing agreement with Sanofi to develop and commercialise extended exposure versions of certain Sanofi mRNA candidates by leveraging ScionxBio’s proprietary TERA platform.
This agreement brings together the global expertise of Sanofi’s mRNA Center of Excellence, with ScionxBio’s TERA platform.
This collaboration represents a critical step in expanding the xRNA modality into a new direction, utilising the technology for novel, long-acting applications across a multitude of potential indications.
Powered by advanced deep learning architectures, the platform deciphers the complex structure-activity relationships (SAR) within high-throughput combinatorial screens to engineer next-generation molecules.
These molecules feature uniquely designed and chemically synthesised regulatory elements that provide greater stability and resistance to enzymatic degradation compared to traditional mRNA, facilitating the sustained, high-level protein expression necessary for therapeutic success in vivo.
While undisclosed, the disease areas covered by the collaboration address conditions where sustained protein expression is essential for robust and competitive clinical effects. The enhanced stability and expression profile of the platform aligns perfectly with the goal of developing life-changing, durable medicines for challenging indications.
ScionxBio will lead optimisation activities up to in vivo validation stages. Sanofi will then assume responsibility for all remaining preclinical development activities, Investigational New Drug (IND)-enabling studies, clinical development, manufacturing, and worldwide commercialisation.
The proprietary technology represents a significant advancement in the mRNA therapeutics field, providing a robust and durable solution for both inherited and acquired protein deficiencies. By utilising an extensive toolbox of well-validated chemical modifications, the technology is poised to transform the treatment landscape for chronic conditions.
Beyond simple protein replacement, the TERA platform is envisioned to produce extended exposure to cardiometabolic or immune corrective modulators, thus potentially serving as a new class of disease-modifying and preventive agents.
